2023
A framework for assessing interactions for risk stratification models: the example of ovarian cancer
Phung M, Lee A, McLean K, Anton-Culver H, Bandera E, Carney M, Chang-Claude J, Cramer D, Doherty J, Fortner R, Goodman M, Harris H, Jensen A, Modugno F, Moysich K, Pharoah P, Qin B, Terry K, Titus L, Webb P, Wu A, Zeinomar N, Ziogas A, Berchuck A, Cho K, Hanley G, Meza R, Mukherjee B, Pike M, Pearce C, Trabert B. A framework for assessing interactions for risk stratification models: the example of ovarian cancer. Journal Of The National Cancer Institute 2023, 115: 1420-1426. PMID: 37436712, PMCID: PMC10637032, DOI: 10.1093/jnci/djad137.Peer-Reviewed Original ResearchConceptsFamily history of ovarian cancerOvarian Cancer Association ConsortiumHistory of ovarian cancerFirst-degree family historyMenopausal statusRisk stratification modelCase-control studyRisk prediction modelOvarian cancerDisease riskAccurate risk stratification modelsStratification modelRisk/protective factorsDepot medroxyprogesterone acetate useProtective factorsFactor analysisRiskComprehensive analysis of interactionsCancerAcetate useUnequivocal riskStatusBreastfeedingAnalysis of interactionsPairwise interactions
2022
Lifestyle and personal factors associated with having macroscopic residual disease after ovarian cancer primary cytoreductive surgery
Phung M, Webb P, DeFazio A, Fereday S, Lee A, Bowtell D, Fasching P, Goode E, Goodman M, Karlan B, Lester J, Matsuo K, Modugno F, Brenton J, Van Gorp T, Pharoah P, Schildkraut J, McLean K, Meza R, Mukherjee B, Richardson J, Grout B, Chase A, Deurloo C, Terry K, Hanley G, Pike M, Berchuck A, Ramus S, Pearce C, Consortium O. Lifestyle and personal factors associated with having macroscopic residual disease after ovarian cancer primary cytoreductive surgery. Gynecologic Oncology 2022, 168: 68-75. PMID: 36401943, PMCID: PMC10398872, DOI: 10.1016/j.ygyno.2022.10.018.Peer-Reviewed Original ResearchConceptsHigh-grade serous ovarian cancerEstrogen-only therapyPrimary cytoreductive surgeryMacroscopic residual diseaseResidual diseaseParous womenFamily history of ovarian cancerOvarian Cancer Association ConsortiumMenopausal hormone therapy useHistory of ovarian cancerFirst-degree family historyCytoreductive surgeryOvarian cancer riskOvarian cancerAdvanced stage high-grade serous ovarian cancerPresence of macroscopic residual diseaseHormone therapy useHigh-grade serous ovarian cancer patientsDepot medroxyprogesterone acetate useBody mass indexLogistic regression modelsOral contraceptive useIncomplete pregnanciesSerous ovarian cancerFactors influencing survival